^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Focus V (anlotinib)

    i
    Other names: AL3818, AL-3818, ALTN, AL 3818
    Company:
    Advenchen, Sino Biopharm
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    21h
    Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances. (PubMed, Clin Transl Oncol)
    Targeted and molecular therapies in EWS show significant promise, particularly in rational combinations that exploit the tumor's dependence on EWS-FLI1-driven transcriptional dysregulation, DNA damage repair deficiencies, or survival signaling. Future research must prioritize biomarker-driven patient selection, integration of multiomics approaches, and multicenter prospective trials to translate these strategies into clinically meaningful improvements in EWS survival.
    Preclinical • Review • Journal • PARP Biomarker • IO biomarker
    |
    EWSR1 (EWS RNA Binding Protein 1) • AURKA (Aurora kinase A) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • CD99 (CD99 Molecule)
    |
    Focus V (anlotinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Yondelis (trabectedin) • Visudyne (verteporfin) • ganitumab (AMG 479) • linsitinib (ASP7487) • ONCT-216 • evofosfamide (IMGS-101) • figitumumab (CP-751,871)
    1d
    MBC-EA: A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates (clinicaltrials.gov)
    P2, N=52, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Focus V (anlotinib) • Halaven (eribulin mesylate)
    1d
    Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment (clinicaltrials.gov)
    P2, N=27, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial primary completion date: Apr 2026 --> Dec 2026
    Trial primary completion date
    |
    Focus V (anlotinib) • Kaitanni (cadonilimab)
    2d
    Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer (clinicaltrials.gov)
    P2, N=34, Completed, Henan Cancer Hospital | Recruiting --> Completed | N=120 --> 34
    Trial completion • Enrollment change
    |
    Imfinzi (durvalumab) • Focus V (anlotinib) • etoposide IV
    3d
    A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Yongxu Jia | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Focus V (anlotinib) • oxaliplatin • Andewei (benmelstobart) • Teysuno (gimeracil/oteracil/tegafur)
    7d
    A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC (clinicaltrials.gov)
    P2, N=48, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    cisplatin • carboplatin • Focus V (anlotinib) • etoposide IV • Andewei (benmelstobart)
    8d
    NeoSACT: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC (clinicaltrials.gov)
    P2, N=29, Completed, Guangdong Provincial People's Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    carboplatin • Focus V (anlotinib) • Tyvyt (sintilimab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    9d
    SOD2-Superoxide Metabolic Axis Regulates Mitophagy and Modulates TKIs Sensitivity in Head and Neck Squamous Cell Carcinoma. (PubMed, Cancer Sci)
    Consistently, SOD2 knockout xenograft models exhibited enhanced antitumor responsiveness to TKIs in vivo. Collectively, these findings identified SOD2 as a key regulator of mitochondrial redox homeostasis and mitophagy, thereby modulating therapeutic sensitivity in HNSCC, and suggest that targeting the SOD2-superoxide metabolic axis may represent a promising strategy to improve TKIs efficacy in HNSCC.
    Journal
    |
    SOD2 (Superoxide Dismutase 2)
    |
    Focus V (anlotinib)
    10d
    Case Report: Hepatoblastoma with spindle cell sarcomatous metastasis in a 14-year-old girl. (PubMed, Front Pediatr)
    Multiple chemotherapy regimens (ifosfamide, carboplatin, and etoposide; and doxorubicin, vincristine, cyclophosphamide, and cisplatin) demonstrated limited efficacy. Subsequent treatment with alternating albumin-paclitaxel, gemcitabine, ifosfamide, and etoposide/cyclophosphamide, irinotecan, and vincristine chemotherapy combined with anlotinib and cranial radiotherapy achieved disease stabilization, with no subsequent progression observed during follow-up. This case highlights the aggressive nature and chemoresistance of the mesenchymal components of HB, emphasizing the need for novel therapeutic approaches that incorporate targeted agents.
    Journal
    |
    AFP (Alpha-fetoprotein) • CD34 (CD34 molecule) • GPC3 (Glypican 3)
    |
    cisplatin • carboplatin • gemcitabine • 5-fluorouracil • Focus V (anlotinib) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine
    11d
    Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Prospective, Single-Arm, Phase II Study(STAR-01) (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Sichuan University
    New P2 trial
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    14d
    The efficacy and safety of tislelizumab plus anlotinib as first-line treatment in advanced pulmonary sarcomatoid carcinoma: a single-arm phase II trial. (PubMed, Clin Cancer Res)
    The combination of tislelizumab and anlotinib demonstrated promising antitumor activity with a manageable safety profile as first-line therapy in patients with advanced PSC.
    P2 data • Journal • PD(L)-1 Biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr)
    17d
    BACON: Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    Focus V (anlotinib) • cyclophosphamide • Andewei (benmelstobart)